- GlobeNewswire•5 days ago
WATERTOWN, Mass., Sept. 22, 2016-- pSivida Corp., a leader in the development of sustained release drug delivery products primarily for eye diseases, announced today that Nancy Lurker, the Company’ s newly-appointed ...
- GlobeNewswire•7 days ago
WATERTOWN, Mass., Sept. 20, 2016-- pSivida Corp., a leader in the development of sustained release drug delivery products primarily for eye diseases, today reported the grant of inducement awards to its ...
- American City Business Journals•12 days ago
Two days after posting dramatic annual losses, Watertown biotech pSivida Corp. has announced CEO Paul Ashton has resigned. The company (PSDV), known for its extended-release drug-and-device combination treatments for diseases that affect the back of the eye, said in a statement Ashton resigned to “pursue other interests." Nancy Lurker, who most recently served as president and CEO of healthcare commercialization company PDI Inc., has been named as president and CEO. Lurker said the executive change had little to do with the losses, but was more about moving the company from R&D to commercialization.
pSivida Corp. (PSDV)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Ask||3.88 x 800|
|Day's Range||3.11 - 3.19|
|52wk Range||2.37 - 5.81|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.65|
|Avg Vol (3m)||74,071|
|Dividend & Yield||N/A (N/A)|